Introduction
Alzheimer’s disease has long been treated with medications that only mask symptoms. Now, two new FDA-approved drugs change that approach. These treatments target the underlying cause of the disease by clearing amyloid plaques from the brain. They can slow memory loss and help patients live longer with greater independence. However, getting these drugs requires meeting specific medical criteria, navigating insurance rules, and understanding real costs. This guide breaks down exactly how these treatments work, who can use them, and what Medicare and private insurance cover.
Understanding the New Alzheimer’s Drugs
Both approved drugs belong to a new class called disease-modifying therapies. They work by binding to amyloid-beta proteins in the brain. Amyloid plaques are sticky protein clusters that disrupt brain cell communication. By removing these plaques, the drugs slow the progression of cognitive decline. Patients do not see an immediate cure, but studies show a measurable slowdown in mental and daily function loss over 18 to 12 months.
Leqembi (Lecanemab)
Leqembi is given through an intravenous infusion every two weeks. It is approved for patients with mild cognitive impairment or mild dementia caused by Alzheimer’s. The drug requires confirmation of amyloid presence through a PET scan or spinal fluid test. Patients must also have regular MRI scans to monitor for brain swelling or tiny bleeds. Clinical trials showed a 27 percent reduction in cognitive decline over 18 months compared to a placebo.
Kisunla (Donanemab)
Kisunla is given as an intravenous infusion once a month. It is approved for the same early-stage patient group. The treatment can be stopped once amyloid plaques are cleared from the brain, which may shorten the total treatment time. Monthly MRI scans are required to check for brain swelling or bleeding. Trial data showed a 35 percent slowdown in cognitive decline over 18 months. Some patients may stop treatment after 11 to 14 months if scans show complete plaque clearance.
Who Qualifies for These Treatments?
Eligibility is strict because these drugs carry serious risks and require close monitoring. You must meet all of the following criteria to start treatment:
- Early disease stage: You must have mild cognitive impairment or mild Alzheimer’s dementia. These drugs do not work for moderate or severe stages.
- Confirmed amyloid pathology: A positive amyloid PET scan or cerebrospinal fluid test is required. Blood tests are not yet approved for diagnosis.
- Age and health status: Most patients are between 60 and 85 years old. You must be healthy enough to sit through a 60-minute infusion and return for monthly MRIs.
- No conflicting medications: You cannot take blood thinners like warfarin or apixaban. These increase the risk of brain bleeding when combined with the drug.
- Carrier protein status: Patients who carry the APOE4 gene variant have a higher risk of brain swelling. Doctors will test for this gene before starting treatment.
If you meet these criteria, a neurologist or memory clinic specialist will guide you through the next steps. Early diagnosis is critical because these drugs only work while brain cells are still active.
How Medicare Covers Disease-Modifying Alzheimer’s Drugs
Medicare covers both Leqembi and Kisunla under a special national coverage policy. This policy applies to Original Medicare and most Medicare Advantage plans. Coverage depends on where you receive the infusion and how your plan is structured.
Original Medicare Coverage
Under Original Medicare, these drugs fall under Part B. You will receive the infusion at a hospital outpatient department or an approved infusion center. Medicare pays 80 percent of the approved amount after you meet your annual Part B deductible. You are responsible for the remaining 20 percent coinsurance. If you have a Medigap plan, it may cover that 20 percent gap. You must use a Medicare-approved facility to avoid denied claims.
Medicare Advantage Coverage
Most Medicare Advantage plans also cover these drugs under Part B. However, each plan has its own network rules. You must use in-network infusion centers to get full coverage. Some plans require prior authorization before the first infusion. Your plan will send a coverage decision letter within 72 hours of the request. If the plan denies coverage, you have the right to file an appeal within 60 days.
Real Out-of-Pocket Costs and Financial Assistance
The list price for these drugs is high, but most patients pay much less due to insurance and manufacturer programs. Understanding the actual costs helps you plan your healthcare budget.
Drug Pricing and Insurance Math
Leqembi costs approximately $26,500 per year. Kisunla costs approximately $27,000 per year. Under Medicare Part B, your 20 percent coinsurance would equal roughly $5,300 to $5,400 annually. Many patients use supplemental insurance to cover that gap. Without supplemental coverage, you would pay the full coinsurance amount each year.
Manufacturer Savings Programs
Both drug makers offer financial help for Medicare beneficiaries. Eisai runs the Leqembi Choice program. It caps out-of-pocket costs at $10 per month for eligible Medicare patients. Lilly offers the Kisunla Access Program. It also caps costs at $10 per month for qualifying Medicare beneficiaries. You must apply through your doctor’s office to enroll. These programs do not cover non-Medicare patients.
Costs for Non-Medicare Patients
Private insurance plans vary widely. Some cover the drugs under Part D, while others use Part B rules. You will likely face a combination of copays, coinsurance, and prior authorization hurdles. Contact your insurance provider to check formulary status and network infusion centers. Many patients use prescription discount cards or patient assistance foundations to lower costs. Charities like the Alzheimer’s Association also provide local resources for financial navigation.
Monitoring and Safety Requirements
Both drugs carry an FDA boxed warning for amyloid-related imaging abnormalities, or ARIA. ARIA causes brain swelling or microbleeds. Symptoms can include headaches, confusion, dizziness, or vision changes. Most cases are mild and resolve on their own. Severe cases require stopping the drug and hospital care. You will need an MRI before starting treatment, then again after the first few doses, and monthly for the first year. Your care team will track your APOE4 status closely. If you experience neurological symptoms, seek medical care right away.
Conclusion
New FDA-approved Alzheimer’s drugs offer real hope for slowing cognitive decline in early-stage patients. Eligibility requires confirmed amyloid pathology, early disease stage, and careful medical screening. Medicare covers both treatments under Part B, but you must use approved facilities and follow plan rules. Out-of-pocket costs can be managed through Medicare supplemental plans and manufacturer savings programs that cap payments at $10 per month. Early diagnosis, proper insurance navigation, and consistent monitoring are the keys to accessing these treatments safely. If you or a loved one shows early memory changes, talk to a neurologist about whether these therapies are a right fit.